<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Hofseth Biocare Asa — News on 6ix</title>
    <link>https://6ix.com/company/hofseth-biocare-asa-1</link>
    <description>Latest news and press releases for Hofseth Biocare Asa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 14 Apr 2026 09:03:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/hofseth-biocare-asa-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d54ea2beedb30cb6f77dd8.webp</url>
      <title>Hofseth Biocare Asa</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1</link>
    </image>
    <item>
      <title>Hofseth BioCare ASA: HBC publishes paradigm-changing clinical trial results of OmeGo full spectrum omegas</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-hbc-publishes-paradigm-changing-clinical-trial-results-of-omego-full-spectrum-omegas</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-hbc-publishes-paradigm-changing-clinical-trial-results-of-omego-full-spectrum-omegas</guid>
      <pubDate>Tue, 14 Apr 2026 09:03:00 GMT</pubDate>
      <description>HBC announces the publication of its head-to-head clinical trial results with its patented, full spectrum omegas brand, OmeGo®. The trial showed that OmeGo® increased the Omega 3 Index (O3I) by over 70% after 14 weeks, over and above a popular omega-3 supplement brand. It was also markedly more effective at reducing inflammatory markers (hsCRP, TNFa and IL-6) which are closely related to the development of ill health. The omega-3 index (O3I) assesses the level of EPA and DHA in red blood cells –</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: HBC ANNUAL REPORT 2025</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-hbc-annual-report-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-hbc-annual-report-2025</guid>
      <pubDate>Fri, 27 Mar 2026 16:08:00 GMT</pubDate>
      <description>The Board of Directors of Hofseth BioCare ASA (&quot;HBC&quot;) has approved the financial statements for 2025, and HBC has today published the Annual Report and Sustainability Report for 2025. In October 2025, the Company announced a successful placing of new ordinary shares with gross proceeds of NOK 158 million. As of the date of this Annual report, the Company has yet to receive all share deposits and has therefore not completed the transaction. The primary cause of the delay is stated to be of a tech</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: FOURTH QUARTER 2025 FINANCIAL REPORT</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-fourth-quarter-2025-financial-report</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-fourth-quarter-2025-financial-report</guid>
      <pubDate>Fri, 13 Feb 2026 07:15:00 GMT</pubDate>
      <description>HBC recorded total operating revenues of NOK 72.2 million in the fourth quarter of 2025, compared to NOK 64.9 million in the same period last year. Net operating revenues were NOK 71.1 million, up from NOK 64.9 million in Q4 2024. Full year 2025, total operating revenues amounted to NOK 256.3 million (265.5). Total operating revenue in 2024 included NOK 8.1 million of gain on sale of assets. EBITDA for the quarter was negative NOK 26.5 million, compared to negative NOK 26.1 million in Q4 2024. F</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: Cancellation of Subsequent Offering – Update on completion of Private Placement</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-cancellation-of-subsequent-offering-update-on-completion-of-private-placement</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-cancellation-of-subsequent-offering-update-on-completion-of-private-placement</guid>
      <pubDate>Mon, 15 Dec 2025 09:04:00 GMT</pubDate>
      <description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to previous announcements by Hofseth BioCare ASA (the &quot;Company&quot;) regarding a subsequent offering with gross proceeds of up to approx. NOK 30,000,000 through iss</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-results-of-subsequent-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-results-of-subsequent-offering</guid>
      <pubDate>Fri, 21 Nov 2025 09:14:00 GMT</pubDate>
      <description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to previous announcements by Hofseth BioCare ASA (the &quot;Company&quot;) regarding a subsequent offering with gross proceeds of up to approx. NOK 30,000,000 through iss</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: Extraordinary General Meeting completed</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-extraordinary-general-meeting-completed</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-extraordinary-general-meeting-completed</guid>
      <pubDate>Thu, 20 Nov 2025 10:30:00 GMT</pubDate>
      <description>Hofseth BioCare ASA held an Extraordinary General Meeting on 20 November 2025. All proposals were resolved as presented in the notice issued on 30 October 2025. The minutes from the Extraordinary General Meeting are attached. For further information, please contact:Jon Olav Ødegård, CEO at HBCE-mail: [email protected] About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and fu</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: LAST DAY OF SUBSCRIPTION PERIOD IN SUBSEQUENT OFFERING</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-last-day-of-subscription-period-in-subsequent-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-last-day-of-subscription-period-in-subsequent-offering</guid>
      <pubDate>Thu, 20 Nov 2025 08:11:00 GMT</pubDate>
      <description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcements by Hofseth BioCare ASA (&quot;HBC&quot; or the &quot;Company&quot;) on 7 November 2025 regarding the terms of a subsequent offering of up to 16,</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: HBC ANNOUNCES STRATEGIC PRODUCT PARTNERSHIP WITH JAMES LAVALLE &amp; METABOLIC ELITE</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-hbc-announces-strategic-product-partnership-with-james-lavalle-and-metabolic-elite</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-hbc-announces-strategic-product-partnership-with-james-lavalle-and-metabolic-elite</guid>
      <pubDate>Thu, 20 Nov 2025 07:58:00 GMT</pubDate>
      <description>Hofseth BioCare (HBC), a global leader in sustainable marine-based nutrition, today announced a strategic product partnership with Metabolic Elite, with formulations being guided by key opinion leader and nutrition expert Jim LaValle. The collaboration unites HBC’s rigorously tested nutritional ingredients, including award-winning ProGo® bioactive peptides, with Metabolic Elite’s advanced performance formulations and LaValle’s expertise in precision health. Together they will develop a premium r</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: Publication of the Prospectus – Start of the Subscription Period for the Subsequent Offering</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-publication-of-the-prospectus-start-of-the-subscription-period-for-the-subsequent-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-publication-of-the-prospectus-start-of-the-subscription-period-for-the-subsequent-offering</guid>
      <pubDate>Mon, 10 Nov 2025 07:33:00 GMT</pubDate>
      <description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth Biocare ASA (&quot;HBC&quot; or the &quot;Company&quot;) on 27 October 2025 regarding completion of a private placement (the &quot;Private</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: Terms of the Subsequent Offering</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-terms-of-the-subsequent-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-terms-of-the-subsequent-offering</guid>
      <pubDate>Fri, 07 Nov 2025 07:55:00 GMT</pubDate>
      <description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth Biocare ASA (&quot;HBC&quot; or the &quot;Company&quot;) on 27 October 2025 regarding completion of a private placement (the &quot;Private</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: THIRD QUARTER 2025 FINANCIAL REPORT</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-third-quarter-2025-financial-report</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-third-quarter-2025-financial-report</guid>
      <pubDate>Fri, 07 Nov 2025 07:00:00 GMT</pubDate>
      <description>HBC recorded total operating revenues of NOK 54.9 million in the third quarter of 2025, compared to NOK 67.9 million in the same period last year. Net operating revenues were NOK 54.8 million, reflecting lower commodity prices and a weaker U.S. dollar during the quarter. EBITDA for the quarter was NOK -21.1 million (-21.0) and the operational EBITDA* amounted to NOK -12.9 million (-13.9m), excluding non-recurring and strategic development costs such as clinical studies, R&amp;D expenses, and Berkåk</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-notice-of-extraordinary-general-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-notice-of-extraordinary-general-meeting</guid>
      <pubDate>Thu, 30 Oct 2025 07:36:00 GMT</pubDate>
      <description>Reference is made to the stock exchange announcement by Hofseth BioCare ASA (&quot;HBC&quot; or the &quot;Company&quot;) on 27 October 2025 regarding (i) the completion of a private placement (the &quot;Private Placement&quot;) of new shares in the Company the &quot;Offer Shares&quot;), the completion of which by delivery of Offer Shares in tranche 2 (the &quot;T2 Offer Shares&quot;) is subject to, among other things, an extraordinary general meeting (the &quot;EGM&quot;) resolving to issue the T2 Offer Shares in the Private Placement and (ii) a potentia</description>
    </item>
    <item>
      <title>Ex. Subsequent Offering Today</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/ex-subsequent-offering-today-1</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/ex-subsequent-offering-today-1</guid>
      <pubDate>Mon, 27 Oct 2025 07:03:00 GMT</pubDate>
      <description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth Biocare ASA (&quot;HBC&quot; or the &quot;Company&quot;) on 27 October 2025 relating to a contemplated subsequent offering of up to 16</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: Key Information Relating to Subsequent Offering</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-key-information-relating-to-subsequent-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-key-information-relating-to-subsequent-offering</guid>
      <pubDate>Mon, 27 Oct 2025 07:02:00 GMT</pubDate>
      <description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth BioCare ASA (&quot;HBC&quot; or the &quot;Company&quot;) on 27 October 2025 regarding completion of a private placement (the &quot;Private</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: Disclosures of Large Shareholdings</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-disclosures-of-large-shareholdings</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-disclosures-of-large-shareholdings</guid>
      <pubDate>Mon, 27 Oct 2025 07:01:00 GMT</pubDate>
      <description>Reference is made to the stock exchange announcement by Hofseth BioCare ASA (&quot;HBC&quot; or the &quot;Company&quot;) on 27 October 2025 regarding completion of a private placement (the &quot;Private Placement&quot;) of new shares in the Company. The following shareholders of the Company have, on 27 October 2025, been allocated new shares in the Private Placement which implies that their holdings have surpassed a notifiable threshold: Guy Urquhart have subscribed for 55,444,444 new shares in the Private Placement. Followi</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: Private placement successfully placed</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-private-placement-successfully-placed</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-private-placement-successfully-placed</guid>
      <pubDate>Mon, 27 Oct 2025 07:00:00 GMT</pubDate>
      <description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement from Hofseth BioCare ASA (&quot;HBC&quot; or the &quot;Company&quot;) published on 24 October 2025 regarding a private placement (the &quot;Private Pl</description>
    </item>
    <item>
      <title>Hofseth Biocare ASA: USD 5 Million Divestment in Aecorbio</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-usd-5-million-divestment-in-aecorbio</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-usd-5-million-divestment-in-aecorbio</guid>
      <pubDate>Fri, 24 Oct 2025 15:56:00 GMT</pubDate>
      <description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. (Ålesund, 24 October 2025) Reference is made to the stock exchange notices published by Hofseth BioCare ASA (&quot;HBC&quot; or the &quot;Company&quot;) earlier today regarding the launch of a priva</description>
    </item>
    <item>
      <title>Hofseth BioCare ASA: Contemplated Private Placement and Partial Divestment of Shares in Aecorbio</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-contemplated-private-placement-and-partial-divestment-of-shares-in-aecorbio</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-contemplated-private-placement-and-partial-divestment-of-shares-in-aecorbio</guid>
      <pubDate>Fri, 24 Oct 2025 15:48:00 GMT</pubDate>
      <description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Hofseth BioCare ASA (&quot;HBC&quot; or the &quot;Company&quot;) today announces a contemplated private placement (the &quot;Private Placement&quot;) of between 86,096,132 and 100,638,889 new shares (&quot;Offer S</description>
    </item>
    <item>
      <title>Hofseth Biocare ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUATION FOR ONGOING FT-002A PEPTIDE DEVELOPMENT IN PROSTATE CANCER</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-aecorbio-secures-a-further-dollar15m-at-a-dollar30m-valuation-for-ongoing-ft-002a-peptide-development-in-prostate-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-aecorbio-secures-a-further-dollar15m-at-a-dollar30m-valuation-for-ongoing-ft-002a-peptide-development-in-prostate-cancer</guid>
      <pubDate>Wed, 17 Sep 2025 06:55:00 GMT</pubDate>
      <description>AecorBio Inc., formerly known as HBC Immunology Inc, has successfully completed a further equity financing round of $1.5m from existing and new investors at a company valuation of $30 million. This funding will enable AecorBio to complete the investigational work of its lead peptide candidate FT-002a, in advanced prostate cancer, to enable an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in 2026. Filing the IND will represent a critical milestone, pa</description>
    </item>
    <item>
      <title>Hofseth Biocare ASA: ProGo, the world’s first consumer health GLP-1 &amp; GIP receptor agonist with muscle mass protection via inhibition of Myostatin and Activin A pathways</title>
      <link>https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-progo-the-worlds-first-consumer-health-glp-1-and-gip-receptor-agonist-with-muscle-mass-protection-via-inhibition-of-myostatin-and-activin-a-pathways</link>
      <guid isPermaLink="true">https://6ix.com/company/hofseth-biocare-asa-1/news/hofseth-biocare-asa-progo-the-worlds-first-consumer-health-glp-1-and-gip-receptor-agonist-with-muscle-mass-protection-via-inhibition-of-myostatin-and-activin-a-pathways</guid>
      <pubDate>Tue, 09 Sep 2025 06:58:00 GMT</pubDate>
      <description>HBC has today released a whitepaper demonstrating how its bioactive peptide ingredient ProGo® uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs to be protected to optimize the benefits of weight loss and support a healthy metabolism. ProGo®️ addresses these needs through its unique triple action properties: highly absorbable protein with a complete amino acid profile to help build muscleantioxidant and anti-inflammatory bioactivity to prote</description>
    </item>
  </channel>
</rss>